{
    "Clinical Trial ID": "NCT00148668",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm 1",
        "  Herceptin/navelbine",
        "INTERVENTION 2: ",
        "  Arm 2",
        "  Taxotere/carboplatin/herceptin"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Patients with stage II or III breast cancer",
        "  HER-2 positive tumors",
        "  Older than 18 years of age",
        "  Eastern Cooperative Oncology Group (ECOG) Performance Status of greater or equal to 1.",
        "  ANC > 1,500/mm3",
        "  Hemoglobin > 9gm/dl",
        "  Platelets > 100,000mm3",
        "  Creatinine < 2mg/dl",
        "  Glucose < 200mg/dl",
        "  Bilirubin < 1.5 x ULN",
        "Exclusion Criteria:",
        "  Previous treatment with herceptin, taxanes, doxorubicin or other anthracycline-type therapy, navelbine, or platinum-based therapy.",
        "  Pregnant or breast-feeding women",
        "  Serious illness, or medical or psychiatric condition",
        "  Uncontrolled infections",
        "  Active or severe cardiovascular or pulmonary disease",
        "  Patients with left ventricular ejection fraction < 50%",
        "  Peripheral neuropathy of any etiology that exceeds grade 1",
        "  Prior history of malignancy",
        "  Uncontrolled diabetes"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Pathological Complete Response After Preoperative Therapy With Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in Patients With HER-2 Positive Early Breast Cancer",
        "  Pathological Complete Response is defined as the complete disappearance of invasive tumor in the breast at the time of surgery",
        "  Time frame: 12 weeks",
        "Results 1: ",
        "  Arm/Group Title: Arm 1",
        "  Arm/Group Description: Herceptin/navelbine",
        "  Overall Number of Participants Analyzed: 41",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  17",
        "Results 2: ",
        "  Arm/Group Title: Arm 2",
        "  Arm/Group Description: Taxotere/carboplatin/herceptin",
        "  Overall Number of Participants Analyzed: 39",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  31"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 5/41 (12.20%)",
        "  Neutropenia  4/41 (9.76%)",
        "  Febrile Neutropenia  0/41 (0.00%)",
        "  SGPT (ALT)  1/41 (2.44%)",
        "Adverse Events 2:",
        "  Total: 5/40 (12.50%)",
        "  Neutropenia  4/40 (10.00%)",
        "  Febrile Neutropenia  1/40 (2.50%)",
        "  SGPT (ALT)  0/40 (0.00%)"
    ]
}